Intra-Cellular Therapies, Inc.
(NASDAQ : ITCI)

( )
ITCI After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
CELGCelgene Corporation
-0.37%86.271.3%$1304.25m
AMGNAmgen Inc.
0.97%203.881.2%$668.70m
GILDGilead Sciences, Inc.
0.77%69.180.9%$573.91m
LOXOLoxo Oncology Inc
0.11%233.5012.7%$483.46m
BIIBBiogen Inc.
-0.27%337.421.3%$447.04m
ILMNIllumina, Inc.
0.87%312.753.5%$347.89m
VRTXVertex Pharmaceuticals Incorporated
2.19%194.701.9%$335.60m
REGNRegeneron Pharmaceuticals, Inc.
0.35%418.842.6%$319.89m
ALXNAlexion Pharmaceuticals, Inc.
2.12%117.052.0%$239.84m
TSROTESARO, Inc.
0.03%74.9614.4%$182.44m
AAgilent Technologies, Inc.
2.10%72.311.5%$161.80m
INCYIncyte Corporation
-0.32%78.422.5%$154.32m
EXASExact Sciences Corporation
4.19%78.8025.3%$153.44m
SRPTSarepta Therapeutics, Inc.
1.22%122.8015.4%$139.57m
LGNDLigand Pharmaceuticals Incorporated
6.49%117.9023.1%$126.24m

Company Profile

Intra-Cellular Therapies, Inc. is a biopharmaceutical company, which focuses on the discovery and clinical development of innovative, small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS. Its lead product candidate, ITI-007, is in clinical development as a first-in-class treatment for schizophrenia. The company also includes pre-clinical programs that are focused on advancing drug candidates for the treatment of cognitive dysfunction, in both schizophrenia and Alzheimer's disease, and for disease modification and the treatment of neurodegenerative disorders, including Alzheimer's disease. The company was founded by Paul Greengard on August 29, 2013 and is headquartered in New York, NY.